TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18688814

Group type: EXPERIMENTAL
Intervention: B. macrostemi plus baseline therapy
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo plus baseline therapy
Number of subjects: 79
Study: 16367880

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Pioglitazone (15, 30, and 45 mg)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 14669295

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 69
Study: 10762100

Group type: EXPERIMENTAL
Intervention: Stage-mismatched intervention (action-oriented activities)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Stage-matched intervention (think more about quitting)
Number of subjects: 92

Group type: COMPARATOR
Intervention: No-intervention condition
Number of subjects: 92
Study: 9266880

Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Talc slurry
Number of subjects: 35

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 35
Study: 8290682

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Bethanechol (placebo-controlled trial)
Number of subjects: 72
Study: 3559982

Group type: EXPERIMENTAL
Intervention: Morphine (7.5, 15, and 30 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pentazocine (22.5, 45, and 90 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ciramadol (30, 60, and 120 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29171112

Group type: EXPERIMENTAL
Intervention: BeWEL intervention (diet and activity programme)
Number of subjects: 163
Study: 27134057

Group type: EXPERIMENTAL
Intervention: Short DAPT (≤6 months)
Number of subjects: 18810

Group type: COMPARATOR
Intervention: Long DAPT (≥12 months)
Number of subjects: 18810
Study: 24588606

Group type: EXPERIMENTAL
Intervention: Emotion Enhanced Triple P (EETP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Group Triple P (GTP)
Number of subjects: 36
Study: 22298568

Group type: EXPERIMENTAL
Intervention: Oral tocotrienols (200 mg mixed tocotrienols, b.i.d.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral tocopherols (200 mg α‐tocopherol, b.i.d.)
Number of subjects: 80
Study: 20102300

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 18245019

Group type: EXPERIMENTAL
Intervention: Metabotropic glutamate receptor agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dopamine receptor‐blocking drugs
Number of subjects: 0
Study: 15914552

Group type: EXPERIMENTAL
Intervention: R-CHOP (375 mg/m2 rituximab with each chemotherapy cycle, n = 99)
Number of subjects: 150

Group type: COMPARATOR
Intervention: CHOP (no immunotherapy, n = 50)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: R-CHOP
Number of subjects: 150

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 150
Study: 12199261

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9885074

Group type: EXPERIMENTAL
Intervention: Tactile discrimination testing in German subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile discrimination testing in Kenyan Masai shepherds
Number of subjects: 0
Study: 7703929

Group type: COMPARATOR
Intervention: Ampho‐B/G (1 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ampho‐B/Lipid (1 mg/kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AmBisome (3 mg/kg)
Number of subjects: 24
Study: 2650734

Group type: EXPERIMENTAL
Intervention: Carbohydrate:fat ratio of 2.64
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate:fat ratio of 0.50
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher carbohydrate:fat ratios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All four meals
Number of subjects: 0
Study: 4348475

Group type: EXPERIMENTAL
Intervention: P1496, a new non-steroidal oestrogen analogue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 495529

Group type: EXPERIMENTAL
Intervention: Written recall
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spoken recall
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Task-motivation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Partially amnesic subjects
Number of subjects: 80

Group type: COMPARATOR
Intervention: Full recall subjects
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonrecall subjects
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hypnotic subjects
Number of subjects: 80
Study: 29771314

Group type: EXPERIMENTAL
Intervention: Bibloc appliance
Number of subjects: 302

Group type: COMPARATOR
Intervention: Monobloc appliance
Number of subjects: 302
Study: 29257754

Group type: EXPERIMENTAL
Intervention: rs6535454 in patients with SAMS (GG=51.1%, GA=40.0%, AA=8.9%)
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: rs4693075 in patients suffering SAMS (CC=36.8%, CG=48.2%, GG=15.0%)
Number of subjects: 1129

Group type: EXPERIMENTAL
Intervention: Haplotype distributions
Number of subjects: 1129
Study: 26282654

Group type: EXPERIMENTAL
Intervention: Mutations in CCND1 and DNA repair pathway alterations (TP53, ATM, ATR, ZNFHX4)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Mutations in IRF4 and EGR1
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: International staging system mutation score
Number of subjects: 463
Study: 23692303

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 20562170

Group type: EXPERIMENTAL
Intervention: Buspirone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen pre-treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone after placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone after estrogen pre-treatment
Number of subjects: 0
Study: 19393480

Group type: EXPERIMENTAL
Intervention: Monascus purpureus Went rice
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no anti-dyslipidemic therapy)
Number of subjects: 72
Study: 18693971

Group type: EXPERIMENTAL
Intervention: Post-test after 0 days
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Post-test after 8 days
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Post-test after 55 days
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Linear regression modeling
Number of subjects: 91
Study: 15448310

Group type: EXPERIMENTAL
Intervention: Emotional stimuli (high arousal negative, low arousal positive)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Emotional stimuli (varied valence and arousal)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Emotional stimuli (Studies 1, 6, and 7)
Number of subjects: 146
Study: 11219208

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (angioplasty and stenting)
Number of subjects: 0
Study: 9538975

Group type: EXPERIMENTAL
Intervention: Sulfonylurea plus metformin
Number of subjects: 591

Group type: COMPARATOR
Intervention: Sulfonylurea alone
Number of subjects: 591
Study: 7735924

Group type: EXPERIMENTAL
Intervention: metronidazole+tetracycline+bismuth subcitrate
Number of subjects: 164

Group type: COMPARATOR
Intervention: omeprazole+amoxycillin+bismuth subcitrate
Number of subjects: 164
Study: 2690897

Group type: EXPERIMENTAL
Intervention: Multifactorial primary prevention intervention (5-year trial)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Randomised non-treated control group
Number of subjects: 612

Group type: COMPARATOR
Intervention: Non-randomised low risk group
Number of subjects: 612
Study: 4558903

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of Delta(9)‐tetrahydrocannabinol and 11‐OH‐Delta(9)‐tetrahydrocannabinol
Number of subjects: 0
Study: 31618272

Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS) applied to the left dorsolateral prefrontal cortex
Number of subjects: 38

Group type: COMPARATOR
Intervention: sham stimulation (control)
Number of subjects: 38
Study: 27767354

Group type: EXPERIMENTAL
Intervention: Orthokeratology contact lenses (OK)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Distance single-vision spectacles (SV) (Control group)
Number of subjects: 30
Study: 26008626

Group type: EXPERIMENTAL
Intervention: Conventional cross-linking (Group I, 36 patients, 3 mW/cm(2) for 30 min)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Accelerated cross-linking (Group II, 36 patients, 9 mW/cm(2) for 10 min)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Accelerated cross-linking (Group III, 33 patients, 18 mW/cm(2) for 5 min)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Accelerated cross-linking (Group IV, 33 patients, 30 mW/cm(2) for 3 min)
Number of subjects: 138
Study: 23663534

Group type: EXPERIMENTAL
Intervention: Mindfulness-based meditation intervention (8 weekly sessions, 90 min each)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the study period)
Number of subjects: 28
Study: 21859484

Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate (BDP) 400 μg b.i.d. plus nebulized salbutamol 2500 μg prn
Number of subjects: 166

Group type: COMPARATOR
Intervention: Nebulized placebo plus nebulized salbutamol 2500 μg prn
Number of subjects: 166
Study: 18762410

Group type: EXPERIMENTAL
Intervention: 1.6g of plant sterol-enriched low-fat fermented milk (FM)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control FM product
Number of subjects: 116
Study: 17317044

Group type: EXPERIMENTAL
Intervention: Early home-based intervention with monthly specific home visits between the infant ages of 5 and 9 months
Number of subjects: 95

Group type: COMPARATOR
Intervention: Routine center-based services (Control)
Number of subjects: 95
Study: 15266884

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11929404

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once a day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Famotidine 20 mg twice a day
Number of subjects: 15
Study: 9842390

Group type: EXPERIMENTAL
Intervention: Social-influences tobacco prevention program with a booster intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education as usual (Control)
Number of subjects: 0
Study: 7978397

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Halothane (HALO)
Number of subjects: 34
Study: 2916514

Group type: EXPERIMENTAL
Intervention: Theophylline (Theo-Dur tablets, 14 to 16 mg/kg per day or their usual dose, whichever was higher)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 17
Study: 768909

Group type: EXPERIMENTAL
Intervention: acebutolol 500 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: bendrofluazide 5-15 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: acebutolol and bendrofluazide in association
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: acebutolol alone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: bendrofluazide alone
Number of subjects: 47
Study: 29393173

Group type: EXPERIMENTAL
Intervention: Needlescopic Cholecystectomy (NSC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Single-Incision Laparoscopic Cholecystectomy (SILC)
Number of subjects: 105
Study: 28449690

Group type: EXPERIMENTAL
Intervention: 3 mg iron as NaFeEDTA
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: 12.5 mg iron as encapsulated ferrous fumarate
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 25429421

Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prostaglandin analog (PGA; travoprost, 0.004%)
Number of subjects: 100
Study: 24079756

Group type: EXPERIMENTAL
Intervention: Mental health training program for primary care health workers
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no mental health training)
Number of subjects: 20
Study: 21171844

Group type: EXPERIMENTAL
Intervention: Television Assisted Prompting (TAP) system
Number of subjects: 3

Group type: COMPARATOR
Intervention: Typical practice delivery conditions
Number of subjects: 3
Study: 20021666

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ), maximum dosage of 200 mg/day, titrated to the best individual dose over 80 weeks.
Number of subjects: 75
Study: 17476515

Group type: EXPERIMENTAL
Intervention: Ilizarov external fixation (IEF)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Unreamed tibial nailing (UTN)
Number of subjects: 61
Study: 15152555

Group type: EXPERIMENTAL
Intervention: Alfetin (biological preparation)
Number of subjects: 0
Study: 11265776

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of recombinant IL-2
Number of subjects: 27
Study: 9408712

Group type: EXPERIMENTAL
Intervention: Behavioral change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study: 8326370

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Acepromazine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Premedicants (Diazepam, Acepromazine, Placebo)
Number of subjects: 43
Study: 2938993

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minocycline
Number of subjects: 0
Study: 30047357

Group type: EXPERIMENTAL
Intervention: Exposure in vivo (EXP), a cognitive-behavioral treatment targeting pain-related fear
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pain-contingent physical therapy (PPT)
Number of subjects: 46
Study: 27146814

Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg ID for 2 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rosuvastatin (10 mg) alone
Number of subjects: 16
Study: 24277351

Group type: EXPERIMENTAL
Intervention: Resourcefulness training reinforced by expressive writing
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Resourcefulness training reinforced by verbal disclosure
Number of subjects: 102

Group type: COMPARATOR
Intervention: Expressive writing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Verbal disclosure
Number of subjects: 102

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 102
Study: 22307571

Group type: EXPERIMENTAL
Intervention: Trophic enteral feeding for the first 6 days
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Full enteral feeding for the first 6 days
Number of subjects: 1000
Study: 19702471

Group type: EXPERIMENTAL
Intervention: Coerced complement nouns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Animacy-violated complement nouns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sentence-final words in coerced sentences
Number of subjects: 0
Study: 17319919

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (QD, n=50)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (BID, n=46)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (QD and BID, n=50 and n=46)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo (n=47)
Number of subjects: 143
Study: 16260822

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy with minimal therapist contact plus participation in a discussion group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participation in a discussion group only (waiting-list control group)
Number of subjects: 0
Study: 12137110

Group type: EXPERIMENTAL
Intervention: Hydrostatic anti-G suit (Libelle; L)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pneumatic anti-G ensemble (AGE-39) with full anti-G straining maneuvers (FM)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pneumatic anti-G ensemble (AGE-39) with reduced anti-G straining maneuvers (RM)
Number of subjects: 3
Study: 10594422

Group type: EXPERIMENTAL
Intervention: rocuronium (20 mg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: vecuronium (4 mg)
Number of subjects: 116
Study: 7540426

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 523

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 523
Study: 1280803

Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 19
Study: 3866411

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% with Ganda 1.0/0.2
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Timolol 0.25% with Ganda 1.0/0.2
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Timolol 0.25%
Number of subjects: 35
Study: 30723945

Group type: EXPERIMENTAL
Intervention: Mucosal incision-assisted biopsy (MIAB)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
Number of subjects: 47
Study: 29752528

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA) counseling
Number of subjects: 336

Group type: COMPARATOR
Intervention: Standard counseling (Control)
Number of subjects: 336
Study: 26207797

Group type: EXPERIMENTAL
Intervention: Ubiquinone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25604606

Group type: EXPERIMENTAL
Intervention: FeSS protocols implementation
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Preimplementation workshops
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Postimplementation survey
Number of subjects: 111
Study: 23580744

Group type: EXPERIMENTAL
Intervention: Cryoballoon with conventional anticoagulation (activated clotting time >250 s)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Multipolar duty‐cycled radiofrequency ablation
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation catheter with aggressive anticoagulation (activated clotting time >320 s)
Number of subjects: 34
Study: 20942267

Group type: EXPERIMENTAL
Intervention: Joba exercise (30-min session per day, 7 times per week, for 3 months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal lifestyle (control group)
Number of subjects: 24
Study: 19140462

Group type: EXPERIMENTAL
Intervention: Endotracheal anesthesia (ETA) with medial approach for resection of segmented intestine and its tumours with colostomy or ileostomy (n = 154) and primary interintestinal anastomoses (n = 18).
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Medial laparotomy under ETA with internal or external colonic decompression without tumour resection.
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Minimally invasive decompressive ileostomy or colostomy under local anesthesia after premedication.
Number of subjects: 552
Study: 16637909

Group type: EXPERIMENTAL
Intervention: Intervention group (IV)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 12812862

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (synthetic estrogens)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Variation in estrogen levels
Number of subjects: 226

Group type: COMPARATOR
Intervention: Oral Contraceptive (OC) use
Number of subjects: 226
Study: 10816903

Group type: EXPERIMENTAL
Intervention: Attention to physical sensations
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Distraction from physical sensations
Number of subjects: 81
Study: 7632156

Group type: EXPERIMENTAL
Intervention: Breath alcohol monitor (Alcomed 3010)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gas chromatography (GC)
Number of subjects: 0
Study: 2507321

Group type: EXPERIMENTAL
Intervention: Intratracheal surfactant (SF‐RI 1) application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 45463

Group type: EXPERIMENTAL
Intervention: Lergotrile mesylate (2 mg oral)
Number of subjects: 16
Study: 31345056

Group type: EXPERIMENTAL
Intervention: Chronotropic Incompetence (CI) group (n = 472)
Number of subjects: 599

Group type: COMPARATOR
Intervention: No-Chronotropic Incompetence (no-CI) group (n = 177)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Heart rate reserve
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Peak VO2
Number of subjects: 599
Study: 31302338

Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-biofeedback (NBF)
Number of subjects: 34
Study: 28675302

Group type: EXPERIMENTAL
Intervention: Emergency endovascular strategy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Emergency endovascular strategy with expert elicitation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Open repair with expert elicitation
Number of subjects: 46
Study: 25568388

Group type: EXPERIMENTAL
Intervention: Operative treatment (posterior or anterior arthrodesis)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nonoperative treatment (body cast or orthosis)
Number of subjects: 47
Study: 23280225

Group type: EXPERIMENTAL
Intervention: ICD Registry patients (MADIT‐II-like)
Number of subjects: 5816

Group type: EXPERIMENTAL
Intervention: ICD Registry patients (SCD‐HeFT-like)
Number of subjects: 5816
Study: 21056418

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg/day
Number of subjects: 60
Study: 18515805

Group type: EXPERIMENTAL
Intervention: Combined endurance-resistance training (CT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Endurance training (ET)
Number of subjects: 58
Study: 17073812

Group type: EXPERIMENTAL
Intervention: High-dose human ALB (albumin) therapy
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 1800